stockportfolio.pro
Stocks / NAMS vs OGN
NAMS vs OGN
NewAmsterdam Pharma Company N.V. and Organon & Co. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| NewAmsterdam Pharma Company N.V. (NAMS) | Organon & Co. (OGN) | |
|---|---|---|
| Market cap | $3.5B | $3.5B |
| Revenue (latest FY) | $22.50M | $6.22B |
| Net income (latest FY) | $-203.82M | $187.00M |
| Revenue growth (5y CAGR) | — | -1.0% |
| Net margin | -905.7% | 3.0% |
| Return on equity | -29.8% | 24.9% |
| P/E ratio | — | 14.4 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 0 | 7 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NAMS — free Open OGN — freeFrequently asked questions
Which is bigger, NAMS or OGN?
NewAmsterdam Pharma Company N.V. is larger by market capitalization — $3.5B versus $3.5B.
Which grows faster, NAMS or OGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.